[
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).",
        "rs value":null,
        "pmid":"PubMed:26508446",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167\/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44\/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).",
        "rs value":null,
        "pmid":"PubMed:24653627",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.",
        "rs value":null,
        "pmid":"PubMed:18794099",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001).",
        "rs value":null,
        "pmid":"PubMed:18003960",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months.",
        "rs value":null,
        "pmid":"PubMed:14993230",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02942706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Erlotinib + FOLFOX",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFOX-4",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00202787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Regorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03992456",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00079066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI + Regorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03698253",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00154102",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study.",
        "rs value":null,
        "pmid":"PubMed:17470858",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01412957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_or_PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Folfirinox + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01328171",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01001377",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03992456",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03087071",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00113763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EGFR CAR-CD3-CD28-4-1BB-expressing autologous T-lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03152435",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01183780",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gatipotuzumab + Tomuzotuximab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03360734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AFM24 + SNK01",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03086538",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trifluridine and tipiracil hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03992456",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI + Imgatuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01326000",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02083653",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03549338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Duligotuzumab + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01652482",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00072748",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nazartinib + TNO155",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03114319",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_S492R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.",
        "rs value":null,
        "pmid":"PubMed:22270724",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_S492R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.",
        "rs value":null,
        "pmid":"PubMed:22270724",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_Amplification_AND_EGFR_EGFR::SEPT14",
        "Disease":"Colon Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":"Case report describing a 63-year-old patient with colorectal adenocarcinoma. He started treatment with XELOX and bevacizumab. After findings of disease progression, they changed to bevacizumab and FOLFIRI. They detected EGFR::SEPT14 fusion (exon 24 & exon 10) and EGFR amplification by NGS on a paraffin sample after discontinuing the treatment due to complications. The tumor was microsatellite stable. The patient started treatment with erlotinib with signs of partial response (CT scan) 20 days later. A couple months later the patient showed signs of progressive disease, but a new variant, EGFRvIII (deletion of Exons 2-7), was detected in the mediastinal lymph nodes sample tested that likely contributed to erolotinib resistance.",
        "rs value":null,
        "pmid":"PubMed:32162810",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_G465R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futuximab\/Modotuximab Mixture",
        "Description":"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab\/panitumumab, prior to Sym004 (Futuximab\/Modotuximab mixture) treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.",
        "rs value":null,
        "pmid":"PubMed:26888827",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_G465R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab\/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro.",
        "rs value":null,
        "pmid":"PubMed:26888827",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HSPH1",
        "Genomic Position":"13:31710765-31736064(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"HSPH1_T17_DELETION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin,Fluorouracil",
        "Description":"329 consecutive patients with stage II\ufffd\ufffd\ufffdIII colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (\ufffd\ufffd\ufffd5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (\ufffd\ufffd\ufffd4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012\ufffd\ufffd\ufffd0.8; P = .03). A significant interaction between chemotherapy and T17 delet",
        "rs value":null,
        "pmid":"PubMed:24512910",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_R201C",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Irinotecan,Vemurafenib",
        "Description":"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression.",
        "rs value":null,
        "pmid":"PubMed:27729313",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.",
        "rs value":null,
        "pmid":"PubMed:22586653",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.",
        "rs value":null,
        "pmid":"PubMed:22586653",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability).",
        "rs value":null,
        "pmid":"PubMed:23348520",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).",
        "rs value":null,
        "pmid":"PubMed:28223103",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab,Pertuzumab",
        "Description":"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.  Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification\/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR).  Patients with HER2-amplified\/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable).",
        "rs value":null,
        "pmid":"PubMed:29320312",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab,Trastuzumab",
        "Description":"In an updated report of a part of the phase 2a MyPathway trial, 57 patients with treatment-refractory, metastatic colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objective response rate was 32% (n=18\/57). One patient had a complete response, and 17 experienced a partial response. Patients were determined to have HER2 amplification by NGS and\/or FISH\/CISH. In addition, the authors note that 27\/35 patients had HER2 overexpression as determined by IHC, 3 of 47 tested had HER2 mutations, 8 had PIK3CA mutations, and 13 had mutated KRAS. Exploratory analysis found that KRAS wild-type patients had better ORR as compared to KRAS mutated patients (40% vs 8%).",
        "rs value":null,
        "pmid":"PubMed:30857956",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Trastuzumab + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03043313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02564900",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Poziotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04172597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Celecoxib + Disitamab vedotin + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05578287",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Disitamab vedotin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05333809",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib,Trastuzumab",
        "Description":"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.",
        "rs value":null,
        "pmid":"PubMed:27108243",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Loperamide + Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01953926",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Chemotherapy + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05193292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pyrotinib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04380012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pyrotinib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04960943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02291289",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03225937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Disitamab vedotin + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05493683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified_and_KRAS_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pyrotinib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04960943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03185988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Disitamab vedotin + Pyrotinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05350917",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03384940",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04744831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:UMIN000027887",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03365882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03225937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03418558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04227041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab + Tucatinib + mFOLFOX6",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05253651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + IAH0968 + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05673512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Disitamab vedotin + Fruquintinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05661357",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pyrotinib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03843749",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified_and_(BRAF_unspecified_or_KRAS_unspecified_or_NRAS_unspecified_or_PIK3CA_unspecified)",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab + Trifluridine and tipiracil hydrochloride + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05356897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04380012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Trastuzumab + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05672524",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified_or_ERBB3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTHFR",
        "Genomic Position":"1:11845780-11863302(-) | 1p36.22",
        "CDS Mutation":null,
        "AA Mutation":"MTHFR_A222V",
        "Disease":"Rectum Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil",
        "Description":"Patients with the wild type (C\/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T\/T).",
        "rs value":null,
        "pmid":"PubMed:26693073",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_Decreased_Peri-therapeutic_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab,Levoleucovorin,Irinotecan,Fluorouracil",
        "Description":"Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.",
        "rs value":null,
        "pmid":"PubMed:25973082",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_Overexpression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.",
        "rs value":null,
        "pmid":"PubMed:25520391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04479436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Siremadlin + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03714958",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_G13D",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",
        "Description":"Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.",
        "rs value":null,
        "pmid":"PubMed:26561417",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FOS",
        "Genomic Position":"14:75745477-75748933(+) | 14q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FOS_Overexpression",
        "Disease":"Colon Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irbesartan",
        "Description":"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",
        "rs value":null,
        "pmid":"PubMed:27022066",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Exon_21_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy,Cetuximab",
        "Description":"Chemotherapy-refractory patients with metastatic colorectal cancer harboring wildtype KRAS and Exon 21 (listed as exon 20 in the source) PIK3CA mutations had lower response rates (0\/9 vs 121\/329; OR: 0.00; p=0.029) and disease control rates as well as shorter progression free and overall survival (median 34 vs 51 weeks; HR: 3.29, p=0.0057) following cetuximab plus chemotherapy than those with wildtype PIK3CA. In multivariate analysis of the KRAS wildtype population, significant associations between PIK3CA exon 21 mutations and poor response to cetuximab were retained. The authors concluded that PIK3CA exon 21 mutation status is more predictive of poor response to cetuximab than PIK3CA mutation status as a whole. They also recommended screening for mutations in the following gene order: KRAS, BRAF, NRAS, PIK3CA exon 21.",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between PIK3CA mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 79 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype PIK3CA (Median PFS: 2.5 and 3.9 months, respectively; p = .014).",
        "rs value":null,
        "pmid":"PubMed:19603024",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Exon20",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02942706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, PIK3CA mutations (H1047R or E545K) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 0\/15 vs 22\/95 for patients harboring PIK3CA mutated or wildtype tumors, respectively; P = 0.038). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of PIK3CA mutation on objective response (P = 0.0337; OR = 0.1153; CI for OR: 0.000\ufffd\ufffd\ufffd0.865). Patients with tumors harboring either PIK3CA H1047R or E545K mutations (15\/109) had decreased PFS, compared to those with wild-type tumors (P = 0.0035), though they had a nonsignificant difference in OS. Authors note a trend in decreasing OS innts with PIK3CA mutated tumors.",
        "rs value":null,
        "pmid":"PubMed:19223544",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03311750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + FOLFIRI + Floxuridine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01312857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + FOLFIRI + Floxuridine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03311750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFOX + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03311750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified_and_PTEN_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Insulin Suppressing Diet + Serabelisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05300048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00565708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin",
        "Description":"This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337\/803, no aspirin use: 466\/803)  and 161 had mutated PIK3CA (aspirin use: 66\/161, no aspirin use: 95\/161). This study found that\ufffd\ufffd\ufffdamong patients with mutated PIK3CA cancer\ufffd\ufffd\ufffd regular use of aspirin following diagnosis was correlated with superior colorectal cancer specific survival (multivariate hazard ratio, 0.18; 95% CI, 0.06-0.61; P<0.001) and overall survival (multivariate hazard ratio, 0.54; 95% CI, 0.31-0.94; P = 0.01). Conversely, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with colorectal cancer\ufffd\ufffd\ufffdspecific survival or overall survival. Among patients with mutated-PIK3CA tumors, 23 of 90 patients who did not use aspirin after diagnosis (26%) died within 5 years after diagnosis, whereas only 2 of 62 reirin after diagnosis (3%) died within 5 years after diagnosis (P<0.001). In contrast, among patients with wild-type PIK3CA tumors, the 5-year cumulative colorectal cancer\ufffd\ufffd\ufffdspecific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92). The authors conclude that PIK3CA mutation may predict response to aspirin therapy in patients with newly diagnosed colorectal c",
        "rs value":null,
        "pmid":"PubMed:23094721",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04753203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03542877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Insulin Suppressing Diet + Serabelisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05300048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MEN1611 + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04495621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Anti-EGFR Monoclonal Antibody",
        "Description":"A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).",
        "rs value":null,
        "pmid":"PubMed:23435830",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01219699",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TVB2640",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980029",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01928459",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Midostaurin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01282502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02861300",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_V955I",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab.",
        "rs value":null,
        "pmid":"PubMed:28424201",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_R93W",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Oxaliplatin,Cetuximab,Fluorouracil",
        "Description":"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old male treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy who experienced progressive disease (PFS: 8 weeks).",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_S158L",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Irinotecan",
        "Description":"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 53 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 1 week; OS: 3 weeks).",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047L",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Irinotecan",
        "Description":"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were males treated with cetuximab + irinotecan as 3rd line therapy and experienced progressive disease. One patient was 73 years old with a PFS of 11 weeks and an OS of 31 weeks. The other patient was 61 years old with a PFS and OS of 4 weeks. Authors concluded from this information and data from larger cohort that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_N345K",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0\/3 and the clinical benefit rate was 2\/3 according to author criteria.",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E545K",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab,Cetuximab",
        "Description":"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response.",
        "rs value":null,
        "pmid":"PubMed:19223544",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Irinotecan,Cetuximab",
        "Description":"Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS, BRAF and NRAS, and had individual response data. All patients were treated with cetuximab and irinotecan, four as 3rd line therapy, one as 4th line. Patient characteristics are as follows: a 65 year old female who experienced stable disease (PFS: 33 weeks, OS: 37 weeks); a 56 year old female who experienced stable disease (PFS: 28 weeks, OS: 43 weeks); a 69 year old female who experienced progressive disease (PFS: 10 weeks, OS: 28 weeks); a 63 year old male who experienced progressive disease (PFS:11 weeks, OS: 18 weeks); a 60 year old female who experienced progressive disease (PFS: 12 weeks, OS: 34 weeks). Based off this information and clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab,Cetuximab",
        "Description":"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumors of four patients (Patient Ids: 7, 42, 52, 64; Table S1) and the metastatic tumor of one patient (11; Table S1), who experienced disease progression following treatment. It was also noted in the primary tumors of 3 patients (25, 48, 88; Table S1) who experienced stable disease following treatment.This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, one patient (38, Table S1) had PIK3CA H1047R as the only noted variant, but experienced partial response.",
        "rs value":null,
        "pmid":"PubMed:19223544",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_V955G",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.V955G mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "rs value":null,
        "pmid":"PubMed:28424201",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_K966E",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.K966E mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "rs value":null,
        "pmid":"PubMed:28424201",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_K944N",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the PIK3CA p.K944N mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "rs value":null,
        "pmid":"PubMed:28424201",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_G1049R",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.",
        "rs value":null,
        "pmid":"PubMed:20619739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_F930S",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA F930S mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "rs value":null,
        "pmid":"PubMed:28424201",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DKK1",
        "Genomic Position":"10:54074056-54077417(+) | 10q21.1",
        "CDS Mutation":null,
        "AA Mutation":"DKK1_NUCLEAR_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Irinotecan,Levoleucovorin,Oxaliplatin,Fluorouracil",
        "Description":"Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)].",
        "rs value":null,
        "pmid":"PubMed:25788273",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_5'_TANDEM_REPEAT",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Irinotecan,Fluorouracil",
        "Description":"The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan\/5FU as first-line chemotherapy were followed in this study.",
        "rs value":null,
        "pmid":"PubMed:20628391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin,Cetuximab,Capecitabine",
        "Description":"In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.",
        "rs value":null,
        "pmid":"PubMed:24957073",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04853043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Folfirinox",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFOX-4",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Siremadlin + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03714958",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03149679",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"NRAS_Q61K_and_TP53_V272M_and_TP53_R273C",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Valproic acid",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.(138+1",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32669268",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.1799T>A",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.V47",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.",
        "rs value":null,
        "pmid":"PubMed:21163703",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a significant association between PTEN protein expression loss and lack of response to panitumumab or cetuximab (P = 0.0012). Patients with PTEN non-expressing tumors (32\/80) had shorter overall survival, compared to those with PTEN expressing tumors (P = 0.0048), though they had a nonsignificant difference in progression free survival (p = .0681).  PIK3CA, PTEN, and KRAS were evaluated for mutations; PTEN loss was the only variant noted in 17 of the patients who experienced either stable disease or disease progression, while the other patients experienced PTEN loss in combination with a KRAS or PIK3CA mutation.",
        "rs value":null,
        "pmid":"PubMed:19223544",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Midostaurin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01282502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02034981",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02638909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_STRN::ALK",
        "Disease":"Colon Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceritinib",
        "Description":"Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumbilica cutaneous metastasis disappeared. Although the size of pelvic tumor by CT scan did not changed, there has been resolution of all contrast enhancing tumor by CT scan.",
        "rs value":null,
        "pmid":"PubMed:26933125",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_CAD::ALK",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"A patient with colorectal cancer harboring a CAD-ALK fusion gene was treated with the ALK inhibitor entrectinib, resulting in durable objective tumor response. A CT scan four weeks after treatment initiation showed a 38% reduction in target lesions, and response was ongoing after 4 months.",
        "rs value":null,
        "pmid":"PubMed:26633560",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HLA-C",
        "Genomic Position":"6:31236526-31239863(-) | 6p21.33",
        "CDS Mutation":null,
        "AA Mutation":"HLA-C_COPY-NEUTRAL_LOSS_OF_HETEROZYGOSITY",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Therapeutic Tumor Infiltrating Lymphocytes",
        "Description":"A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D and HLA-C*08:02. A single lesion that progressed after 9 months still expressed the KRAS G12D mutation. Whole-exome analysis revealed copy-neutral loss of heterozygosity at chromosome 6, encoding the HLA locus and resulting in loss of the targeted HLA-C*08:02 allele.",
        "rs value":null,
        "pmid":"PubMed:27959684",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15\ufffd\ufffd\ufffdmonths, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutate",
        "rs value":null,
        "pmid":"PubMed:23374602",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.73; interaction test results were significant [P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.01]). Results were less clear for response rate (interaction P\ufffd\ufffd\ufffd",
        "rs value":null,
        "pmid":"PubMed:26867820",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"CCDC6-RET_fusion_COSF1271",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_CCDC6::RET",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":"A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 19 months on treatment.",
        "rs value":null,
        "pmid":"PubMed:29538669.0",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e11-e10",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI\/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months.",
        "rs value":null,
        "pmid":"PubMed:26546295",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_G595R_and_G667C",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Entrectinib",
        "Description":"A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI\/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling.",
        "rs value":null,
        "pmid":"PubMed:26546295",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e11-e10",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5\ufffd\ufffd\ufffdRACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 m",
        "rs value":null,
        "pmid":"PubMed:26563355",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab,Cetuximab",
        "Description":"In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient).",
        "rs value":null,
        "pmid":"PubMed:26508446",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_Deletion",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fluorouracil",
        "Description":"A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056).",
        "rs value":null,
        "pmid":"PubMed:12237773",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>T",
        "AA Mutation":"p.G12C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>T",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20361188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26644315",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20361188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>T",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25137394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.181C>G",
        "AA Mutation":"p.Q61E",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>T",
        "AA Mutation":"p.G12V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>A",
        "AA Mutation":"p.G12S",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>T",
        "AA Mutation":"p.G12C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>T",
        "AA Mutation":"p.G12V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.182",
        "AA Mutation":"p.Q61P",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5E",
        "Genomic Position":"6:86159809-86205496(+) | 6q14.3",
        "CDS Mutation":null,
        "AA Mutation":"NT5E_Overexpression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.",
        "rs value":null,
        "pmid":"PubMed:25520391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ARAF",
        "Genomic Position":"X:47420516-47431299(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"ARAF_S490T",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib,Cetuximab,Irinotecan",
        "Description":"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.",
        "rs value":null,
        "pmid":"PubMed:27729313",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"JUN",
        "Genomic Position":"1:59246465-59249785(-) | 1p32.1",
        "CDS Mutation":null,
        "AA Mutation":"JUN_Overexpression",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irbesartan",
        "Description":"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",
        "rs value":null,
        "pmid":"PubMed:27022066",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALCAM",
        "Genomic Position":"3:105085753-105295744(+) | 3q13.11",
        "CDS Mutation":null,
        "AA Mutation":"ALCAM_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fluorouracil",
        "Description":"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1\ufffd\ufffd and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.003; HR 5.61; 95% ",
        "rs value":null,
        "pmid":"PubMed:24708484",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D579del",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y578C",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2458G>T",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N655T",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27864817",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18830121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2009C>T",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.K818",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2464A>T",
        "AA Mutation":"p.N822Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2146G>A",
        "AA Mutation":"p.D716N",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2447A>G",
        "AA Mutation":"p.D816G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2460T>A",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2040T>G",
        "AA Mutation":"p.N680K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>A",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26316776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G60R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G60D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.37G>C",
        "AA Mutation":"p.G13R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>T",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G13R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP1R15A",
        "Genomic Position":"19:49375649-49379314(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP1R15A_RS557806",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI Regimen,Bevacizumab",
        "Description":"Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032).",
        "rs value":null,
        "pmid":"PubMed:27177629",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EPHB4",
        "Genomic Position":"7:100400187-100425121(-) | 7q22.1",
        "CDS Mutation":null,
        "AA Mutation":"EPHB4_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Bevacizumab",
        "Description":"EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC.",
        "rs value":null,
        "pmid":"PubMed:23579861",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EREG",
        "Genomic Position":"4:75230860-75254468(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"EREG_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.",
        "rs value":null,
        "pmid":"PubMed:23374602",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EREG",
        "Genomic Position":"4:75230860-75254468(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"EREG_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.73; interaction test results were significant [P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.01]). Results were less clear for response rate (interaction P\ufffd\ufffd\ufffd",
        "rs value":null,
        "pmid":"PubMed:26867820",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Tepotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04515394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Irinotecan + Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01075048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01892527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02008383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02034981",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Savolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03592641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RC108",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05628857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_N375S",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02008383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib,Crizotinib",
        "Description":"Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3\/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues. Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro. The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06\/16) without significant toxicity.",
        "rs value":null,
        "pmid":"PubMed:27325282",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan",
        "Description":"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07.",
        "rs value":null,
        "pmid":"PubMed:24256029",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan",
        "Description":"498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).",
        "rs value":null,
        "pmid":"PubMed:19775480",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KDR",
        "Genomic Position":"4:55944644-55991756(-) | 4q12",
        "CDS Mutation":"c.2518C>T",
        "AA Mutation":"p.L840F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29588308",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HSPA5",
        "Genomic Position":"9:127997132-128003609(-) | 9q33.3",
        "CDS Mutation":null,
        "AA Mutation":"HSPA5_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil",
        "Description":"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU.",
        "rs value":null,
        "pmid":"PubMed:23456958",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05201612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Elimusertib + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04535401",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trifluridine and tipiracil hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04166604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04096417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01676714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04096417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01888965",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Best supportive care + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02149108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.170A>C",
        "AA Mutation":"p.K57T",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26644315",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F129L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PD0325901",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22402123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V211D",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Binimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31227518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04853043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Midostaurin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01282502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03839342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + FOLFIRI + Floxuridine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01312857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EPCAM",
        "Genomic Position":"2:47596287-47614173(+) | 2p21",
        "CDS Mutation":null,
        "AA Mutation":"EPCAM_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin + Atorvastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04379999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04096417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Oblimersen sodium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004870",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ROS1",
        "Genomic Position":"6:117609463-117747018(-) | 6q22.1",
        "CDS Mutation":null,
        "AA Mutation":"ROS1_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Bevacizumab + CEA-targeted adenoviral vaccine + Capecitabine + FOLFOX",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03050814",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine + LBL-007",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine + LBL-007 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fruquintinib or Regorafenib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04483219",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + mFOLFOX6",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fruquintinib + Tislelizumab + Vitamin E",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05771181",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05009069",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Favezelimab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05064059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-4280A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05600309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab-Relatlimab-rmbw",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05328908",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"large intestine | adenoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02563002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05310643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Emepepimut-S + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01507103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01507103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01876511",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02813824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | adenoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00952016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, NY-ESO-1, PRAME and Survivin-specific allogenic CTLs",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02494167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + WT1-A10\/AS01B immunotherapeutic GSK2130579A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01819558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":null,
        "AA Mutation":"FLT3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":null,
        "AA Mutation":"FLT3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02390947",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    }
]